Free Trial
OTCMKTS:GNMSF

Genmab A/S (GNMSF) Stock Price, News & Analysis

Genmab A/S logo
$213.00 +3.50 (+1.67%)
(As of 05:32 PM ET)

About Genmab A/S Stock (OTCMKTS:GNMSF)

Key Stats

Today's Range
$202.00
$213.50
50-Day Range
$198.00
$234.80
52-Week Range
$192.20
$334.33
Volume
1,848 shs
Average Volume
2,837 shs
Market Capitalization
$13.92 billion
P/E Ratio
20.48
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Stock News Headlines

TD Cowen Reaffirms Their Hold Rating on Genmab (GMAB)
Genmab A/S: Circling Back On This Complicated Story
Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong
Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.
Genmab A/S Expands Share Capital and Warrants
Genmab Discloses Share Transactions by Executives
Jefferies Sticks to Their Hold Rating for Genmab A/S (0MGB)
See More Headlines

GNMSF Stock Analysis - Frequently Asked Questions

Genmab A/S's stock was trading at $315.6999 at the beginning of 2024. Since then, GNMSF stock has decreased by 32.5% and is now trading at $213.00.
View the best growth stocks for 2024 here
.

Genmab A/S (OTCMKTS:GNMSF) released its earnings results on Wednesday, November, 5th. The company reported $0.47 earnings per share for the quarter, beating the consensus estimate of $0.45 by $0.02. The firm had revenue of $45.65 million for the quarter, compared to the consensus estimate of $53.94 million. Genmab A/S had a net margin of 23.49% and a trailing twelve-month return on equity of 17.73%.

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
11/05/2014
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:GNMSF
Employees
2,204
Year Founded
1999

Profitability

Net Income
$631.91 million
Pretax Margin
32.75%

Debt

Sales & Book Value

Annual Sales
$2.39 billion
Cash Flow
$12.76 per share
Book Value
$59.44 per share

Miscellaneous

Free Float
N/A
Market Cap
$13.92 billion
Optionable
Not Optionable
Beta
1.03

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (OTCMKTS:GNMSF) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners